Hoth Therapeutics (HOTH)
(Delayed Data from NSDQ)
$1.32 USD
-0.06 (-4.35%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HOTH 1.32 -0.06(-4.35%)
Will HOTH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HOTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HOTH
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
HOTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
Other News for HOTH
Hoth Therapeutics (HOTH) Receives Buy Rating from D. Boral Capital | HOTH Stock News
Hoth Therapeutics (HOTH) Expands Phase II Trial for Skin Toxicity Treatment
Hoth Therapeutics extending Phase II trial of HT-001 in cancer patients to EU
Hoth Therapeutics Announces Engagement with ICON and Expansion of Phase II Clinical Trial for ...
HOTH Stock: D. Boral Capital Maintains Buy Rating and $5 Price Target | HOTH Stock News